Skip to main content
    V

    Voyager Therapeutics Inc (VYGR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.06
    +0.05 (+2.49%)

    Market Cap: $132.48M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    +54.91%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.42
    Range$-0.80 - $-0.28
    10 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.48+13.8%
    60d ago$-0.48+13.8%
    30d ago$-0.48+12.0%
    7d ago$-0.420.0%
    Current$-0.42
    Revenue Consensus
    $6M
    Range$31000 - $15M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.24
    Range$-1.16 - $0.22
    10 analysts
    Revenue Consensus
    $574830
    Range$-7900880 - $30M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.24---
    Sep 26EST
    		-$-0.42---
    Jun 26
    Reported Aug 6
    		$-0.40$-0.55+27.27%Beat+29.8%
    Mar 26
    Reported May 7
    		$-0.47$-0.53+11.32%Beat+11.3%
    Dec 25
    Reported Mar 9
    		$-0.47$-0.51+7.93%Beat+20.3%
    Sep 25
    Reported Nov 10
    		$-0.47$-0.52+9.62%Beat-193.7%
    Jun 25
    Reported Aug 6
    		$-0.57$-0.52-9.62%Miss-216.7%
    Mar 25
    Reported May 6
    		$-0.53$-0.44-20.45%Miss-165.0%
    Dec 24
    Reported Mar 11
    		$-0.59$-0.35-68.43%Miss-147.2%
    Sep 24
    Reported Nov 12
    		$-0.16N/A+60.00%Beat+72.9%
    Jun 24
    Reported Aug 6
    		$-0.18N/A+55.00%Beat+64.7%
    Mar 24
    Reported May 13
    		$-0.20N/A+52.38%Beat-106.8%
    Dec 23
    Reported Feb 28
    		$1.25$-0.29+531.03%Beat+304.9%
    Sep 23
    Reported Nov 6
    		$-0.59$-0.60+1.67%Beat-231.1%
    Jun 23
    Reported Aug 3
    		$-0.51$-0.56+8.93%Beat-2.0%
    Mar 23
    Reported May 9
    		$2.94$1.26+133.33%Beat+625.0%
    Dec 22
    Reported Mar 7
    		$-0.61$-0.55-10.91%Miss-506.7%
    Sep 22
    Reported Nov 8
    		$0.45$-0.41+209.76%Beat+167.2%
    Jun 22
    Reported Aug 4
    		$-0.50$-0.42-19.05%Miss+37.5%
    Mar 22
    Reported May 4
    		$-0.56$-0.34-64.71%Miss+3.4%
    Dec 21
    Reported Mar 8
    		$0.15N/A+145.45%Beat+134.9%
    Sep 21
    Reported Nov 2
    		$-0.67$-0.73+8.22%Beat-129.5%
    Jun 21
    Reported Aug 9
    		$-0.80$-0.68-17.65%Miss-247.8%
    Mar 21
    Reported May 10
    		$-0.58$-0.66+12.12%Beat+12.1%
    Dec 20
    Reported Feb 25
    		$-0.43$-0.57+24.56%Beat-26.5%
    Sep 20
    Reported Nov 9
    		$2.27$0.20+1035.00%Beat+653.7%
    Jun 20
    Reported Aug 10
    		$-0.23N/A+66.67%Beat-179.3%
    Mar 20
    Reported May 6
    		$-0.66$-0.81+18.52%Beat+18.5%
    Dec 19
    Reported Mar 3
    		$-0.34N/A+58.02%Beat+51.4%
    Sep 19
    Reported Nov 6
    		$-0.41$-0.67+38.81%Beat+34.9%
    Jun 19
    Reported Aug 9
    		$0.29N/A+136.25%Beat+136.3%
    Mar 19
    Reported May 7
    		$-0.81$0.58-239.66%Miss-28.6%
    Dec 18
    Reported Feb 26
    		$-0.70$-0.71+1.41%Beat-75.0%
    Sep 18
    Reported Nov 7
    		$-0.63$-0.76+17.11%Beat+29.2%
    Jun 18
    Reported Aug 7
    		$-0.80$-0.66-21.21%Miss-9.6%
    Mar 18
    Reported May 10
    		$-0.63$-0.61-3.28%Miss+3.1%
    Dec 17
    Reported Mar 14
    		$-0.40$-0.72+44.44%Beat+29.8%
    Sep 17
    Reported Nov 2
    		$-0.89$-0.71-25.35%Miss-
    Jun 17
    Reported Aug 8
    		$-0.73$-0.59-23.73%Miss-
    Mar 17
    Reported May 9
    		$-0.65$-0.53-22.64%Miss-
    Dec 16
    Reported Mar 15
    		$-0.57$-0.45-26.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.14EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-834.00%
    ROE-54.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.51xQuick Ratio7.51x
    Trading Statistics
    Beta1.28Avg Volume771.77K
    52-Week High$5.4852-Week Low$1.99

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.31
    SMA 20$2.58
    SMA 50$3.01
    SMA 200$3.58
    EMA 10$2.30
    EMA 20$2.52
    EMA 50$2.87
    EMA 200$3.41

    MACD

    Line: -0.27Signal: -0.23Hist: -0.04

    ADX

    ADX: 49.5+DI: 6.6-DI: 37.5

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$2.32

    Bollinger Bands

    Upper Band$3.22
    Lower Band$1.93
    %B Position5037%(Upper)
    Band Width0.10

    RSI (14-Day)

    Oversold
    22.3

    Momentum Oscillators

    Stoch %K4.8
    Stoch %D4.3
    Williams %R-90.2
    ROC (10d)-23.0%
    Momentum-0.61
    CCI (20d)-141.2
    MFI (14d)23.5

    Volatility Measures

    ATR (14d)$0.15(7.2%)
    StdDev (20d)0.32
    Hist Vol60.2%(High)

    Volume Flow

    VWAP$2.05
    OBV8.5M
    AD Line-15.8M
    CMF (20d)-0.228

    Volume Metrics

    Avg Vol (20d)783.2K
    Vol Ratio0.9x
    VWMA (20d)$2.50

    Pivot Points

    R3$2.31
    R2$2.24
    R1$2.12
    Pivot Point$2.06
    S1$1.94
    S2$1.87
    S3$1.76

    Advanced Oscillators

    TSI-51.71
    Ultimate Osc32.8
    KST-264.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.17M$2.59M$15.34M$13.37M$5.20M$6.47M$6.28M$24.63M$29.58M$19.52M$90.06M$4.61M
    Cost of Revenue$0$0$1.05M$0$0$0$32.81M$0$0$0$1.33M$0
    Gross Profit$3.17M$2.59M$15.34M$13.37M$5.20M$6.47M$6.28M$24.63M$29.58M$19.52M$90.06M$4.61M
    Operating Expenses$29.56M$32.86M$45.27M$43.96M$41.83M$41.17M$44.58M$38.41M$44.60M$35.70M$36.00M$34.12M
    R&D$22.04M$24.60M$35.95M$35.87M$31.33M$31.53M$35.58M$30.24M$34.45M$27.09M$25.76M$25.86M
    SG&A$7.52M$8.26M$9.32M$8.09M$10.49M$9.64M$8.99M$8.17M$10.15M$8.61M$10.24M$8.26M
    Operating Income$-26,392,000$-30,270,000$-29,932,000$-30,594,000$-36,625,000$-34,693,000$-38,299,000$-13,780,000$-15,025,000$-16,183,000$54.06M$-29,507,000
    Interest Income$1.53M$1.91M$2.11M$2.38M$2.83M$3.29M$3.99M$4.58M$4.89M$4.87M$3.15M$3.43M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-24,453,000$-27,923,000$-27,417,000$-27,809,000$-33,367,000$-30,984,000$-33,903,000$-9,001,000$-10,117,000$-11,316,000$57.22M$-26,078,000
    Income Tax Expense$20,000$14,000$9,000$83,000$15,000$37,000$584,000$43,000$24,000$14,000$822,000$-177,000
    Net Income$-24,473,000$-27,937,000$-27,426,000$-27,892,000$-33,382,000$-31,021,000$-34,487,000$-9,044,000$-10,141,000$-11,330,000$56.40M$-25,901,000
    EBITDA$-25,321,000$-29,268,000$-29,009,000$-29,916,000$-35,924,000$-34,259,000$-38,399,000$-14,509,000$-16,077,000$-16,918,000$53.60M$-30,369,000
    EBIT$-25,981,000$-29,835,000$-29,528,000$-30,194,000$-36,198,000$-34,275,000$-37,897,000$-13,580,000$-15,005,000$-16,183,000$54.06M$-29,507,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VYGR

    News

    Voyager Therapeutics stock trades at EUR 1.80 as revenue falls to USD 3.17 million

    Voyager Therapeutics (VYGR) stock is trading at EUR 1.80 as the company reported a drop in second-quarter revenue to USD 3.17 million, down from USD 5.20 million in the previous year. Despite the revenue decline...

    ad-hoc-news.de•10/15/26•Somewhat-Bearish

    Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

    Voyager Therapeutics (NASDAQ:VYGR) is identified as a high-risk investment due to its substantial cash burn and declining revenue. The company's cash runway is estimated at only 11 months...

    Simply Wall Street•10/9/26•Bearish

    Wells Fargo maintains Buy on Voyager Therapeutics stock at USD 10.00

    Wells Fargo has reiterated its Buy rating on Voyager Therapeutics (VYGR) stock, setting a price target of USD 10.00. This follows the company's Q2 2026 revenue of USD 3.17 million and a narrowed GAAP net loss of USD...

    AD HOC NEWS•10/7/26•Somewhat-Bullish

    Voyager Therapeutics stock gets Wells Fargo Buy rating and USD 10 target

    Wells Fargo has maintained its Buy rating for Voyager Therapeutics (VYGR) stock and set a price target of USD 10.00...

    AD HOC NEWS•10/6/26•Bullish

    VT6 Forecast — Price Target — Prediction for 2027

    This article provides a forecast for Voyager Therapeutics, Inc. (VT6) stock, including analyst price targets and future predictions. It details the company's financial performance, such as recent earnings and revenue...

    TradingView•9/30/26•Neutral

    VYGR Valuation and Fair Value

    P/E
    -1.1x
    Forward P/E
    8.4x
    PEG
    0.0x
    P/B
    0.8x
    See GNG's fair value

    VYGR Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -834.0%
    Net margin
    0.0%
    ROE
    -54.1%
    FCF margin
    -352.4%

    VYGR Competitors

    CompanyTicker
    Tiziana Life Sciences LtdTLSA
    Health Catalyst IncHCAT
    AN2 Therapeutics IncANTX
    Korro Bio, Inc.KRRO
    Owlet IncOWLT
    OrganiGram Holdings IncOGI
    Anavex Life Sciences CorpAVXL
    MaxCyte IncMXCT

    Sector: Healthcare

    VYGR Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    0
    Buy
    11
    Hold
    0
    Sell
    0
    Strong Sell
    0

    VYGR Bull Case vs Bear Case

    Bull case

    • 100.0% of VYGR's analyst ratings are Buy or Strong Buy.

    Bear case

    • VYGR's quarterly revenue changed -39.1% year over year.

    VYGR Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    2.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.42
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About VYGR

    Does VYGR pay dividends?

    Voyager Therapeutics Inc (VYGR) does not currently pay a regular dividend.

    What is VYGR's market cap?

    Voyager Therapeutics Inc (VYGR) has a market capitalization of $132.48M with a current stock price of $2.06.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In